BEN BOSWELL: Open Payments
NPI 1528316122 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,303 in 51 payments from 12 companies in 2025. Trend: 2023 $817 · 2024 $1,065 · 2025 $1,303
Food & beverage: $1,303
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 13 | $320 |
| Janssen Pharmaceuticals, Inc | 12 | $259 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $254 |
| TRICE MEDICAL, INC. | 2 | $193 |
| Otsuka America Pharmaceutical, Inc. | 4 | $84 |
| Alkermes, Inc. | 2 | $46 |
| E.R. Squibb & Sons, L.L.C. | 2 | $43 |
| ABBVIE INC. | 1 | $26 |
| Collegium Pharmaceutical, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $21 |
Products named: INGREZZA, INVEGA SUSTENNA, CAPLYTA, ABILIFY ASIMTUFII, ARISTADA, COBENFY, REXULTI, VRAYLAR.
Industry payments across PA — which companies pay providers there.
